LAMN cancer guide graphic: low-grade appendiceal mucinous neoplasm explained, pathology, treatment, and follow-up, from Appendicure

LAMN Cancer: Low-Grade Appendiceal Mucinous Neoplasm Explained

LAMN cancer is the common name for a low-grade appendiceal mucinous neoplasm, a slow-growing tumor of the appendix that makes mucus. When it stays inside the appendix and is removed with clean edges, the 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium recommend appendectomy alone, with follow-up scans for some people. When mucus or tumor cells have escaped the appendix, the plan changes, and that is what this page walks through.

Most people hear the words LAMN cancer for the first time after what they thought was a routine appendectomy. The surgeon removes an inflamed appendix, the pathology report comes back a week later, and suddenly there is a four-letter diagnosis nobody in the room can explain well. We built this page to answer the questions we hear most often in the Appendicure community: what LAMN is, what the report means, how it is treated, and what follow-up looks like.

Everything here follows the 2025 consensus guidelines led by Dr. Elizabeth Godfrey and colleagues at Yale and the PSM Consortium, plus the international pathology definitions that doctors use to classify these tumors. Sources are listed at the bottom so you can read them yourself.

What LAMN cancer is

LAMN stands for low-grade appendiceal mucinous neoplasm. The cells lining the tumor make mucus, and under the microscope they look only mildly abnormal, which is what low-grade means. A LAMN grows by pushing against the wall of the appendix instead of invading through it in the destructive way an adenocarcinoma does.

In 2016, an international group of pathologists called the Peritoneal Surface Oncology Group International (PSOGI) agreed on the names doctors should use. They kept the term low-grade appendiceal mucinous neoplasm, recommended dropping the older word cystadenoma, and reserved the term mucinous adenocarcinoma for tumors that show true infiltrative invasion. If an older report says mucinous cystadenoma or mucinous neoplasm of uncertain malignant potential, it is usually describing the same kind of tumor now called LAMN.

Patients and search engines both call it LAMN cancer, so this page does too. Doctors often avoid the word cancer for a LAMN that stays inside the appendix, because it is not invasive. LAMN still needs care and follow-up, because pseudomyxoma peritonei (PMP), the condition where mucus and tumor cells spread inside the abdomen, usually starts from a mucinous tumor of the appendix such as a LAMN.

LAMN, HAMN, and mucinous adenocarcinoma

Three diagnoses get confused all the time. A LAMN has low-grade cells and no infiltrative invasion. A high-grade appendiceal mucinous neoplasm, or HAMN, grows the same way but has high-grade cells. A mucinous adenocarcinoma has invaded the tissue around it. The difference changes treatment, so it is worth asking your doctor which one your report says. The types of appendix cancer page compares all of them side by side.

How LAMN is usually found

Many LAMNs are found by accident. Someone has an appendectomy for appendicitis and the pathologist finds the tumor. Others show up on a CT scan done for something else, where the appendix looks swollen with mucus. The 2025 guidelines list imaging signs that raise suspicion, including swelling at the tip of the appendix, a size over 2 centimeters, curved calcium deposits in the wall, and an irregular wall without the fat stranding that usually comes with infection.

Once a LAMN is suspected or confirmed, the guidelines recommend a full workup before deciding anything else:

  • A detailed history and physical exam.
  • Blood tumor markers: CEA, CA-125, and CA 19-9, with CRP considered.
  • A CT or MRI of the abdomen and pelvis, if it has not been done.
  • A colonoscopy, because a separate growth in the colon is found in a meaningful share of these patients.
  • Review of the tissue by an expert pathologist, and discussion of the case at a multidisciplinary tumor board.

The guidelines also say patients should be checked for support needs, including support groups, social work, financial help, emotional support, and fertility counseling.

Reading a LAMN pathology report

The pathology report decides almost everything that comes next. These are the findings that matter most:

  • Margins. A negative margin means no tumor at the cut edge of the specimen. A positive margin with tumor cells is handled differently from mucin alone at the edge.
  • Perforation. Whether the appendix wall broke open, even microscopically.
  • Mucin outside the appendix. Whether there is mucus on the outside of the appendix or in the abdomen.
  • Acellular or cellular mucin. Acellular mucin has no tumor cells in it. Cellular mucin contains tumor cells. This one distinction carries a large difference in the risk of the disease coming back.

LAMN also has its own staging rules. Under the current TNM system, a LAMN confined to the muscle wall of the appendix is staged Tis(LAMN). The T1 and T2 categories do not apply to LAMN. Mucin or tumor reaching the layer just under the surface is T3, and mucin or tumor on the outer surface of the appendix or its fatty attachment is T4a. Mucin out in the abdomen is coded in the M category: M1a for acellular mucin only, and M1b when the mucin contains tumor cells. For more help with the vocabulary, the understanding your pathology post and the glossary are good next stops.

Treatment for LAMN cancer under the 2025 guidelines

The biggest change in the 2025 guidelines is a push toward the least invasive surgery that gets clean margins. Over 130 specialists voted on each step, and every step reached more than 90 percent agreement. The pathway below follows the order of the guideline.

If the LAMN was found on a scan first

The next step is surgery by the least invasive safe approach, which for most people is diagnostic laparoscopy. If the surgeon sees anything that looks like spread to the lining of the abdomen, biopsies are taken.

If there is no visible spread

The guidelines recommend appendectomy alone, done to a negative margin. If the margins are clean and there is no perforation and no mucin or tumor cells outside the appendix, follow-up scans are used selectively, and many people will not need them. The guidelines point out that risk is never zero, because an appendix can perforate and seal itself again.

If there was a microscopic perforation or surface mucin

If margins are clean but the report shows a microscopic perforation, or mucin or tumor cells only on the surface of the appendix, regular surveillance is recommended. The guidelines still count this as a negative margin.

If tumor cells are at the margin

When living tumor cells (not mucin alone) are at the cut edge, the guidelines recommend a repeat operation to get a clean margin, using the most conservative resection possible, such as a cuff resection, and avoiding a bowel reconnection when possible. Regular surveillance follows. For people at high risk from surgery, watching closely may be a reasonable choice.

If acellular mucin was found near the appendix

If the only disease outside the appendix is acellular mucin close to it, and the surgeon removed all of it, no more surgery is needed. The guidelines put the recurrence rate in this group as low as 4 percent, and recommend regular surveillance. If acellular mucin in that area was left behind, for example after an operation at another hospital, the guidelines recommend an evaluation for cytoreductive surgery, with or without intraperitoneal chemotherapy.

If mucin has spread further or contains tumor cells

Acellular mucin spread beyond the area around the appendix, or any cellular mucin, moves care to the peritoneal disease pathway. The guidelines cite recurrence estimates of 33 to 75 percent for localized cellular mucin, similar to more widespread disease, which is why a more aggressive approach is recommended. A recurrence found during surveillance is also treated as peritoneal disease.

The guidelines do not route a LAMN confined to the appendix to a right hemicolectomy. Their recommendation is appendectomy to a negative margin. If a larger colon operation has been suggested for a LAMN, it is a fair question to ask why, and a second opinion at a center that treats appendix tumors often is reasonable. The medical centers and providers page lists centers with this experience.

Surveillance after LAMN

When surveillance is recommended, the 2025 guidelines describe what it should include:

  • A visit with a history and physical exam.
  • A CT or an MRI of the abdomen and pelvis. Either is acceptable. The guidelines suggest choosing one and sticking with it, based on what your center does well.
  • A CEA blood test, plus any other tumor marker that was high at diagnosis or at any later point.
  • A schedule of every 6 to 12 months for 5 to 10 years. Higher-grade tumors and any spread to the abdominal lining call for closer follow-up.

The guidelines note that recurrence is most common in the first 3 years after surgery and levels off at about 6 years. They do not recommend circulating tumor DNA (ctDNA) blood tests for surveillance, and they reserve a second-look laparoscopy for select high-risk cases. Two Appendicure posts go deeper on follow-up: LAMN surveillance with MRI and LAMN after appendectomy.

When LAMN spreads: pseudomyxoma peritonei

If LAMN cells escape the appendix and keep making mucus inside the abdomen, the result is pseudomyxoma peritonei. In LAMN, this is usually low-grade disease. Part 2 of the 2025 guidelines recommends evaluation for cytoreductive surgery for most patients with low-grade peritoneal disease who are healthy enough for it. That surgery, often paired with heated chemotherapy (HIPEC), belongs at a center with real experience in it. The guidelines also say that when the disease in the abdomen is higher grade than the tumor in the appendix, the abdominal disease guides treatment. The post on the difference between LAMN and PMP explains how the two connect.

The genetics of LAMN

Small sequencing studies show a consistent pattern. In a 2020 study that included 8 LAMNs, every LAMN carried a KRAS mutation, 5 of the 8 carried a GNAS mutation, and none had TP53 or ATM mutations. A 2024 study from Germany of 52 tumors, including LAMN and PMP, found KRAS mutations in 98 percent and GNAS mutations in about 56 percent, with more mutations piling up as disease progressed. Both are small retrospective studies, so these numbers are estimates, not rules. The 2025 guidelines say tumor genetic testing may be considered for appendiceal mucinous neoplasms, but that there is little evidence yet on how it should change treatment.

That gap is one of the reasons the Appendicure registry exists. Pooling molecular and pathology data from many patients with LAMN is how researchers can start to learn which patterns predict recurrence and which treatments help.

Add your LAMN data to the registry

The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including LAMN. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.

Already enrolled? Add new reports or correct your record.

Frequently asked questions about LAMN cancer

Is LAMN cancer?

LAMN is a low-grade tumor that does not invade the way an adenocarcinoma does, so many doctors avoid calling it cancer when it stays inside the appendix. It is staged with appendix cancers, it can spread inside the abdomen as pseudomyxoma peritonei, and it needs proper treatment and follow-up.

Do I need a right hemicolectomy for LAMN?

For a LAMN with no visible spread, the 2025 consensus guidelines recommend appendectomy alone to a negative margin. If tumor cells are at the margin, they recommend the most conservative repeat resection possible, such as a cuff resection.

Do I need chemotherapy for LAMN?

The 2025 guidelines do not include chemotherapy in the treatment of a LAMN that is confined to the appendix. If LAMN has spread into the abdomen, treatment follows the peritoneal disease pathway, where cytoreductive surgery is the main option for most people with low-grade disease.

How long is follow-up after LAMN?

When surveillance is recommended, the guidelines suggest a CT or MRI and a CEA blood test every 6 to 12 months for 5 to 10 years.

What is the difference between acellular and cellular mucin?

Acellular mucin is mucus with no tumor cells in it. Cellular mucin contains tumor cells. Cellular mucin outside the appendix carries a much higher chance of the disease coming back and moves care to the peritoneal disease pathway.

Is LAMN the same as HAMN?

No. Both grow without infiltrative invasion, but HAMN has high-grade cells and LAMN has low-grade cells. They are staged and treated differently.

Sources

  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
  • Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the PSOGI modified Delphi process. Am J Surg Pathol. 2016;40(1):14-26. doi.org/10.1097/PAS.0000000000000535
  • The Royal College of Pathologists. Appendix staging (UICC TNM 9). rcpath.org
  • Liao X, Vavinskaya V, Sun K, et al. Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology. 2020;76(3):461-469. doi.org/10.1111/his.13986
  • Doll J, Maurus K, Köhler F, et al. Molecular profiling of low-grade appendiceal mucinous neoplasms (LAMN). Genes Chromosomes Cancer. 2024;63(10):e23270. doi.org/10.1002/gcc.23270

Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.